Navigation Links
Mylan Launches Generic Version of Cyklokapron® Injection
Date:12/2/2011

PITTSBURGH, Dec. 2, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its business Mylan Institutional has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Tranexamic Acid Injection, 100 mg/mL, packaged in 1,000 mg/10 mL Single-dose Vials. This product is the generic version of Pharmacia & Upjohn's Cyklokapron® Injection, which is indicated for short-term use in patients with hemophilia to reduce or prevent hemorrhage during and following oral surgery.

Tranexamic Acid Injection had U.S. sales of approximately $17 million for the 12 months ending Sept. 30, 2011, according to IMS Health. Mylan is shipping this product immediately.

Currently, Mylan has 165 ANDAs pending FDA approval representing $99.4 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $26.9 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
2. Mylan Launches Generic Version of Caduet® Tablets
3. Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
4. Mylan Committed to Expanding Access in Developing Countries to High Quality, Affordable HIV/AIDS Treatment
5. Mylan Receives Approval for Generic Version of Zinecard® for Injection
6. Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot®
7. Mylan Successfully Upsizes and Completes Refinancing of Credit Facility
8. Mylan Applauds Obama Administrations Call to Create an "AIDS-Free Generation" Through Global Fight Against HIV/AIDS
9. Mylan to Acquire Pfizer Respiratory Delivery Platform
10. Mylan Receives Approval for Generic Version of MS Contin® Tablets
11. Mylan Launches First Generic Version of Exelon® Capsules in the U.K.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Israel , December 5, 2016 ... identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase ... BL-8040, the Company,s leading oncology platform at the ongoing 58th ... San Diego, California . ... , , ...
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 ... showed non-inferiority to hydroxyurea (HU) in Complete Hematologic Response (CHR) ... tolerability profile of ropeginterferon alfa-2b versus HU ... long-term follow-up trial CONTINUATION-PV to obtain European marketing authorization in ... this data to the FDA as it seeks approval for ...
(Date:12/4/2016)... HOUSTON , Dec. 3, 2016   Pairnomix, LLC, ... Precision Medicine Alliance (PEPMA) recognized by the White House, today ... individualized approach to the identification of candidate therapies for a ... SCN8A gene were presented at the 70 th ... in Houston, TX , December 2-6, 2016.  ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... ... it has been featured in SuperbCrew magazine, a leading online tech news platform ... This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility security ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... today that nominations will be accepted from December 5, 2016 through March ... Awards include the Information Security Executive® of the Year, which recognizes executives ...
(Date:12/5/2016)... ... December 05, 2016 , ... Researchers at Johns Hopkins All ... brains of young athletes. Over the course of three years, researchers will study concussions ... guards. The mouth guards, equipped with special sensors, will track the location and force ...
(Date:12/5/2016)... ... December 05, 2016 , ... Worldwise ®, a leading ... firm kathy ireland® Worldwide for five additional years, announced by Kevin Fick, Worldwise ... licensing agreement three years ago to design and develop the kathy ireland® Loved ...
(Date:12/5/2016)... ... December 05, 2016 , ... “Epilepsy Awareness,” which can be ... sparks a conversation about epilepsy, bearing down on the social stigma and lack ... diagnosed with epilepsy within their lifetime. With such a large percentage of people ...
Breaking Medicine News(10 mins):